Company
ExeVir Bio
ExeVir develops novel antibody therapies capable of preventing and treating current public health threats and responding to future outbreaks with speed and agility.
Also known as ExeVir, Exevir Bio BV
- Status
- Operatingas of 2026-09-17Source (opens in a new tab)
- Business model
- B2B
- Legal name
- Exevir Bio BV
Claim, correct or request removal
Record updated 29 September 2026
About
Based on our unique modular and multi-specific single domain antibody (VHH) platform, we are building a pipeline of antibody therapies. We aim to tackle the growing impact of infectious diseases, with an initial focus on COVID-19 and dengue, to help the most vulnerable patients, including the immunocompromised.
About the company
- Status notes
- We are a clinical stage company and have demonstrated the ability to fast-track antibody drug development.
Loading relationship preview